Many monoclonal antibodies are discovered from non-human species. Of the 107 antibody-based therapeutics approved for use in the USA and/or Europe, approximately 15% are murine and 12% are chimeric. Because non-humanized antibodies and chimeras (human Fc backbone) are often highly immunogenic, the advent of human-antibody producing transgenic animals and humanization techniques can lower the risk of patient immunogenicity. Over 70% of the approved antibody therapeutics are fully human or humanized.
LakePharma has developed an efficient platform for complementarity-determining regions (CDR) grafting, which involves transferring the antibody (CDRs) into a proper human antibody framework while retaining its original affinity and specificity. Using LakePharma's T20 Score Analyzer tool, users are able to calculate a monoclonal antibody humanness score to distinguish between human and non-human antibodies. If you are seeking both humanization and affinity maturation, the LakePharma HuMAT™ platform leverages our capabilities in CDR grafting and display discovery to offer a one-step antibody humanization and affinity maturation with time and cost savings, all while delivering consistent high-quality antibody leads.
Humanization workflow at LakePharma
Humanization and HuMAT™ projects are customizable and the number of molecules can be increased.
Download our Antibody Discovery and Engineering Services Brochure by clicking here.
Discovery of Potent, Functional Anti-BTLA, and Anti-TIGIT Monoclonal Antibodies using Hybridoma and Phage Display Platform webinar recording available NOW!
|1019||HuMAT™ Antibody Humanization and Affinity Maturation||4 to 6 months||Request|
|24401||Antibody Humanization and Affinity Measurement||8 to 9 weeks||$52,000|